You searched for "macular"
Atrophy and anti-VEGF
1 August 2019
| Saruban Pasu
|
EYE - Vitreo-Retinal
The aim of this study was to investigate treatment factors, along with ocular and systemic factors for their association with macular atrophy (MA) incidence in eyes with neovascular age-related macular degeneration (nAMD) treated with anti-VEGF aflibercept or ranibizumab according to...
VEGF and axial length (RVU)
1 April 2015
| Saruban Pasu
|
EYE - Vitreo-Retinal
The authors of this paper set out to examine whether the concentrations of VEGF in the vitreous were associated with refractive error and axial length in eyes without retinal disease, except of macular holes or epiretinal membranes. A vitreous sample...
Screening for Sickle Cell Retinopathy (SCR): Why we do wide-field imaging, OCT/OCT-A for SCR – Newcastle upon Tyne Hospitals NHS Foundation Trust
I have been working in ophthalmology for over five years as a photographer and research co-ordinator, and it is fascinating, rewarding, and interesting to learn all about the different diseases associated with the eye. One condition that has been a...
Why is there subretinal fluid at the macula?
3 June 2021
| Zhihang Cheng
|
EYE - Vitreo-Retinal
|
Central serous chorioretinopathy (CSC), Differential diagnosis, Retinal disease, Serous fluid accumulation, Serous maculopathy
This is a review article looking at the differential diagnosis of subretinal fluid in the macula that could be diagnosed as central serous chorioretinopathy (CSCR). The authors have categorised them into 12 groups: neovascular diseases, vitelliform lesions, inflammatory diseases, ocular...
RaScaL Study
1 June 2015
| Sofia Rokerya
|
EYE - Vitreo-Retinal
The RaScaL study was a six month, single-centre, controlled, prospective phase I/II study in which subjects with diabetic macular oedema (DME) and associated peripheral nonperfusion on ultrawide-field fluorescein angiography (UWFA) were randomised to: (1) study arm: ranibizumab (0.5 mg) injection...
First treatment for late-stage dry AMD rejected by UK drug regulator
Leading sight loss charity the Macular Society has responded to the decision not to approve the first potential treatment for geographic atrophy (GA) or late stage dry aged-related macular degeneration. The decision is a significant setback for those affected by...
Combined anti-VEGF and PDT for wet AMD
1 February 2014
| Brian Ang
|
EYE - Vitreo-Retinal
The authors report on a retrospective case series of combined anti-VEGF and photodynamic therapy (PDT) in the treatment of wet age-related macular degeneration (AMD) refractory to anti-VEGF monotherapy alone. The criteria for treatment failure of anti-VEGF monotherapy were persistent subretinal...
Corneal dystrophies simplified
1 February 2017
| Bushra Thajudeen
|
EYE - Cornea
Based on biomicroscopic and histopathologic features, corneal dystrophies can be broadly classified into epithelial, Bowman’s layer / anterior stromal, stromal, and endothelial dystrophies. Corneal dystrophies are a group of inherited, bilateral, gradually progressing, non- inflammatory conditions caused by accumulation of...
Data update for leading causes of CVI in England and Wales
In this article the authors present an epidemiological update, based on certifiable visual impairment (CVI) registration for figures for sight impairment (SI) in England and Wales from the last report of 2007-2008 to the current data for April 2012 to...Moorfields: The 2025 macula course
2 June 2025
-5 June 2025
The 2025 Macula course will take place from 2nd - 5th June 2025. Bookings are now open. Retinal diseases are a major cause of blindness. Diagnostic investigations, understanding of disease mechanisms, new therapies, and the evidence base, have all evolved...
Is an increased homocysteine level associated with greater risk of AMD?
1 June 2015
| Jonathan CP Roos
|
EYE - Vitreo-Retinal
Basic research studies have implicated homocysteine in causing vascular endothelial dysfunction and inflammation, and this has been borne out in large observational studies which suggested that elevated homocysteine is associated with increased risk of cardiovascular disease. In order to determine...
Ocular complications in retinal vasculitis
1 February 2018
| Efrosini Papagiannuli
|
EYE - Vitreo-Retinal
In this retrospective study the authors aimed to characterise the incidence rates of visual loss and ocular complications associated with retinal vasculitis (RV – annual incidence of 1-2/ 100000/ per annum). A secondary objective was to compare the visual outcomes...
